OBJECTIVES: A literature search revealed no prior study on the direct medical costs for gynecologic cancer, including uterine, cervical, ovarian and other gynecologic cancers. The study objective was to estimate the direct healthcare costs of gynecologic cancers among community-dwelling U.S. residents from an all-payer perspective. METHODS: A retrospective cross-sectional analysis was conducted using the 2007-2011 Medical Expenditure Panel Survey (MEPS) databases for patients with gynecologic cancers. Direct healthcare costs in the U.S. were estimated using gynecologic cancer-related expenditures by source of payment and service type. Generalized linear models with a gamma distribution and a log link were used to estimate adjusted mean expenditures based on patients’ characteristics. Costs were adjusted to 2011 U.S. dollars using the Consumer Price Index-Medical (CPI-M). RESULTS: A total of 282 patients (average annual weighted N=568,245) were identified with gynecologic cancer diagnoses across the study years. The estimated annual direct healthcare cost attributable to gynecologic cancers was $3.86 billion.  The estimated average annual direct healthcare cost per patient was $6,794 (standard error [SE]=$1,269). Medicare accounted for most of the total expenditures (44%), followed by private insurance (38%). Over half (56%) of the total costs were generated by inpatient hospitalizations. The annual predicted costs (SE) per patient were $5,887 ($1,059) in patients with one type of gynecologic cancer and $13,129 ($6,573) in patients with two different types of gynecologic cancers. The annual predicted cost (SE) per patient with ovarian cancer was $15,693 ($7,912), which was higher than that for uterine ($9,590±$3,636) and cervical cancers ($7,935±$3,668). CONCLUSIONS: Gynecologic cancers place a considerable economic burden on society. The majority of expenditures was driven inpatient hospitalizations and Medicare accounted for the largest portion of payments. This study can provide better understanding of the economic burden of gynecologic cancers and contribute to future policy on gynecologic cancer prevention and control programs.